Inflammatory bowel disease (IBD) is a type of chronic, non-specific inflammatory disorders of unknown etiology, which can involve the entire gastrointestinal tract. The disease was first documented around two hundred years ago, but it wasn't until the middle of the last century that people began to recognize it gradually. Over the decades, the treatment of IBD has made a leap from "no cure" to the age of biological agents. Today, there is growing experience with aminosalicylic acid agents, glucocorticoids, immunosuppressants, biologics and small molecule drugs in the treatment of IBD, This article reviews IBD and the selection of related drugs to provide more references for promoting the development of new drugs and clinical treatment.

1.Chang JT. Pathophysiology of inflammatory bowel diseases[J]. N Engl J Med, 2020, 383(27): 2652-2664. DOI: 10.1056/NEJMra2002697.

2.Actis GC, Pellicano R, Fagoonee S, et al. History of inflammatory bowel diseases[J]. J Clin Med, 2019, 8(11): 1970. DOI: 10.3390/jcm8111970.

3.Beiranvand M. A review of the biological and pharmacological activities of mesalazine or 5-aminosalicylic acid (5-ASA): an anti-ulcer and anti-oxidant drug[J]. Inflammopharmacology, 2021, 29(5): 1279-1290. DOI: 10.1007/s10787-021-00856-1.

4.Kirsner JB. Historical origins of medical and surgical therapy of inflammatory bowel disease[J]. Lancet, 1998, 352(9136): 1303-1305. DOI: 10.1016/S0140-6736(98)11132-7.

5.Baron JH, Connell AM, Lennard-Jones JE, et al. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis[J]. Lancet, 1962, 1(7239): 1094-1096. DOI: 10.1016/s0140-6736(62)92080-9.

6.Dick AP, Grayson MJ, Carpenter RG, et al. Controlled trial of sulphasalazine in the treatment of ulcerative colitis[J]. Gut, 1964, 5: 437-442. DOI: 10.1136/gut.5.5.437.

7.Watkinson G. Sulphasalazine: a review of 40 years' experience[J]. Drugs, 1986, 32 (Suppl 1): 1-11. DOI: 10.2165/00003495-198600321-00003.

8.Azad KA, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine[J]. Lancet, 1977, 2(8044): 892-895. DOI: 10.1016/s0140-6736(77)90831-5.

9.Criscuoli V, Modesto I, Orlando A, et al. Mesalazine for the treatment of inflammatory bowel disease[J]. Expert Opin Pharmacother, 2013, 14(12): 1669-1678. DOI: 10.1517/14656566.2013.808622.

10.Ko CW, Singh S, Feuerstein JD, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis[J]. Gastroenterology, 2019, 156(3): 748-764. DOI: 10.1053/j.gastro.2018.12.009.

11.Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment[J]. J Crohns Colitis, 2020, 14(1): 4-22. DOI: 10.1093/ecco-jcc/jjz180.

12.Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease[J]. Trends Pharmacol Sci, 2013, 34(9): 518-530. DOI: 10.1016/j.tips.2013.07.003.

13.Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial[J]. Br Med J, 1955, 2(4947): 1041-1048. DOI: 10.1136/bmj.2.4947.1041.

14.Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis[J]. Br Med J, 1962, 2(5321): 1708-1711. DOI: 10.1136/bmj.2.5321.1708.

15.Truelove SC, Willoughby CP, Lee EG, et al. Further experience in the treatment of severe attacks of ulcerative colitis[J]. Lancet, 1978, 2(8099): 1086-1088. DOI: 10.1016/s0140-6736(78)91816-0.

16.Summers RW, Switz DM, Sessions JJ, et al. National cooperative Crohn's disease study: results of drug treatment[J]. Gastroenterology, 1979, 77(4 Pt 2): 847-869. https://pubmed.ncbi.nlm.nih.gov/38176/.

17.Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment[J]. Gastroenterology, 1984, 86(2): 249-266. https://pubmed.ncbi.nlm.nih.gov/6140202/.

18.Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease[J]. N Engl J Med, 1994, 331(13): 842-845. DOI: 10.1056/NEJM199409293311304.

19.Manguso F, Bennato R, Lombardi G, et al. Efficacy and safety of oral beclomethasone dipropionate in ulcerative colitis: a systematic review and meta-analysis[J]. PLoS One, 2016, 11(11): e166455. DOI: 10.1371/journal.pone.0166455.

20.Keenan GF. Management of complications of glucocorticoid therapy[J]. Clin Chest Med, 1997, 18(3): 507-520. DOI: 10.1016/s0272-5231(05)70398-1.

21.Edsbäcker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease[J]. Clin Pharmacokinet, 2004, 43(12): 803-821. DOI: 10.2165/00003088-200443120-00003.

22.Cross RK. Safety considerations with the use of corticosteroids and biologic therapies in mild-to-moderate ulcerative colitis[J]. Inflamm Bowel Dis, 2017, 23(10): 1689-1701. DOI: 10.1097/MIB.0000000000001261.

23.Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease[J]. J Endocrinol, 2003, 178(3): 339-346. DOI: 10.1677/joe.0.1780339.

24.Bruscoli S, Febo M, Riccardi C, et al. Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice[J]. Front Immunol, 2021, 12: 691480. DOI: 10.3389/fimmu.2021.691480.

25.Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine[J]. Med J Aust, 1962, 49(2): 592-593. https://pubmed.ncbi.nlm.nih.gov/13969929/.

26.Summers RW, Switz DM, Sessions JJ, et al. National cooperative Crohn's disease study: results of drug treatment[J]. Gastroenterology, 1979, 77(4 Pt 2): 847-869. https://pubmed.ncbi.nlm.nih.gov/38176/.

27.Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study[J]. N Engl J Med, 1980, 302(18): 981-987. DOI: 10.1056/NEJM198005013021801.

28.Axelrad JE, Roy A, Lawlor G, et al. Thiopurines and inflammatory bowel disease: current evidence and a historical perspective[J]. World J Gastroenterol, 2016, 22(46): 10103-10117. DOI: 10.3748/wjg.v22.i46.10103.

29.Goldberg R, Irving PM. Toxicity and response to thiopurines in patients with inflammatory bowel disease[J]. Expert Rev Gastroenterol Hepatol, 2015, 9(7): 891-900.DOI: 10.1586/17474124.2015.1039987.

30.Kaplan MM, Arora S, Pincus SH. Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy.  Clinical and histologic response[J]. Ann Intern Med, 1987, 106(2): 231-235. DOI: 10.7326/0003-4819-106-2-231.

31.Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with  refractory inflammatory bowel disease[J]. Ann Intern Med, 1989, 110(5): 353-356. DOI: 10.7326/0003-4819-110-5-353.

32.Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators[J]. N Engl J Med, 2000, 342(22): 1627-1632.DOI: 10.1056/NEJM200006013422202.

33.Johnson CM, Dassopoulos T. Update on the use of thiopurines and methotrexate in inflammatory bowel disease[J]. Curr Gastroenterol Rep, 2018, 20(11): 53. DOI: 10.1007/s11894-018-0658-1.

34.Quezada SM, McLean LP, Cross RK. Adverse events in IBD therapy: the 2018 update[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(12): 1183-1191. DOI: 10.1080/1747 4124.2018.1545574.

35.Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis[J]. Lancet, 1990, 336(8706): 16-19. DOI: 10.1016/0140-6736(90)91521-b.

36.Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy[J]. N Engl J Med, 1994, 330(26): 1841-1845. DOI: 10.1056/NEJM199406303302601.

37.Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous  cyclosporine in severe ulcerative colitis[J]. Gastroenterology, 2003, 125(4): 1025-1031. DOI: 10.1016/s0016-5085(03)01214-9.

38.Grazie ML, Bagnoli S, Dragoni G, et al. Infliximab is more effective than cyclosporine as a rescue therapy for acute  severe ulcerative colitis: a retrospective single-center study[J]. Ann Gastroenterol, 2021, 34(3): 370-377. DOI: 10.20524/aog.2021.0584.

39.McDonald JW, Feagan BG, Jewell D, et al. Cyclosporine for induction of remission in Crohn's disease[J]. Cochrane Database Syst Rev, 2005, (2): D297. DOI: 10.1002/14651858.CD000297.pub2.

40.Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications[J]. Ther Adv Chronic Dis, 2018, 9(2): 65-72. DOI: 10.1177/2040622317742095.

41.Singh S, Allegretti JR, Siddique SM, et al. AGA technical review on the management of moderate to severe ulcerative colitis[J]. Gastroenterology, 2020, 158(5): 1465-1496. DOI: 10.1053/j.gastro.2020.01.007.

42.Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020[J]. J Gastroenterol, 2021, 56(6): 489-526. DOI: 10.1007/s00535-021-01784-1.

43.Waters MF, Laing AB, Ambikapathy A, et al. Treatment of ulcerative colitis with thalidomide[J]. Br Med J, 1979, 1(6166): 792. DOI: 10.1136/bmj.1.6166.792.

44.Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial[J]. Gastroenterology, 1999, 117(6): 1271-1277. DOI: 10.1016/s0016-5085(99)70276-3.

45.Bramuzzo M, Ventura A, Martelossi S, et al. Thalidomide for inflammatory bowel disease: systematic review[J]. Medicine (Baltimore), 2016, 95(30): e4239. DOI: 10.1097/MD.0000000000004239.

46.Peng X, Lin ZW, Zhang M, et al. The efficacy and safety of thalidomide in the treatment of refractory Crohn's  disease in adults: a double-center, double-blind, randomized-controlled trial[J]. Gastroenterol Rep (Oxf), 2022,10: c52.DOI: 10.1093/gastro/goac052.

47.Dai C, Huang YH, Jiang M. Combination therapy in inflammatory bowel disease: current evidence and  perspectives[J]. Int Immunopharmacol, 2023, 114: 109545.DOI: 10.1016/j.intimp.2022.109545.

48.Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease[J]. Lancet, 1993, 342(8864): 173-174. DOI: 10.1016/0140-6736(93)91375-v.

49.Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group[J]. N Engl J Med, 1997, 337(15): 1029-1035. DOI: 10.1056/NEJM199710093371502.

50.Melsheimer R, Geldhof A, Apaolaza I, et al. Remicade® (infliximab): 20 years of contributions to science and medicine[J]. Biologics, 2019, 13: 139-178. DOI: 10.2147/BTT.S207246.

51.Peyrin-Biroulet L, Sandborn WJ, Panaccione R, et al. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues[J]. Therap Adv Gastroenterol, 2021, 14: 1088242930. DOI: 10.1177/17562848211059954.

52.Buchner AM, Schneider Y, Lichtenstein GR. Biosimilars in inflammatory bowel disease[J]. Am J Gastroenterol, 2021, 116(1): 45-56. DOI: 10.14309/ajg.0000000000000844.

53.Grossberg LB, Papamichael K, Cheifetz AS. Review article: emerging drug therapies in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2022, 55(7): 789-804. DOI: 10.1111/apt.16785.

54.Wang CJ, Byun MJ, Kim SN, et al. Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment[J]. J Control Release, 2022, 345: 1-19.DOI: 10.1016/j.jconrel.2022.02.028.

55.Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease[J]. World J Gastroenterol, 2018, 24(17): 1868-1880. DOI: 10.3748/wjg.v24.i17.1868.

56.Vedolizumab Intravenous (IV) compared to placebo in chinese participants with Crohn's disease - study results - clinicaltrials.gov[EB/OL]. (2022-09-21) [2022-11-26]. https://www.clinicaltrials.gov/ct2/show/results/NCT03234907?term=Vedolizumab&cntry=CN&draw=4&rank=6&view=results.

57.唐健, 邓钧, 黄梓城, 等. 单中心回顾性研究维得利珠单克隆抗体治疗活动期克罗恩病的真实世界疗效及安全性[J]. 中华炎性肠病杂志, 2022, 6(3): 217-222. [Tang J, Deng J, Huang ZC, et al. The real-world efficacy and safety of vedolizumab in the treatment of active Crohn's disease: a single center retrospective study[J]. Chinese Journal of Inflammatory Bowel Diseases, 2022, 6(3): 217-222.] DOI: 10.3760/cma.j.cn101480-20220110-00009.

58.Al-Bawardy B, Shivashankar R, Proctor DD. Novel and emerging therapies for inflammatory bowel disease[J]. Front Pharmacol, 2021, 12: 651415. DOI: 10.3389/fphar.2021.651415.

59.Gubatan J, Keyashian K, Rubin S, et al. Anti-integrins for the treatment of inflammatory bowel disease: current evidence and perspectives[J]. Clin Exp Gastroenterol, 2021, 14: 333-342. DOI: 10.2147/CEG.S293272.

60.Deepak P, Loftus EJ. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy[J]. Drug Des Devel Ther, 2016, 10: 3685-3698.DOI: 10.2147/DDDT.S102141.

61.Baumgart C, Le Berre C. Newer biologic and small-molecule therapies for inflammatory bowel disease[J]. N Engl J Med, 2021, 385(14): 1302-1315. DOI: 10.1056/NEJMra1907607.

62.Almradi A, Hanzel J, Sedano R, et al. Clinical trials of IL-12/IL-23 inhibitors in inflammatory bowel disease[J]. BioDrugs, 2020, 34(6): 713-721. DOI: 10.1007/s40259-020-00451-w.

63.Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med, 2017, 376(18): 1723-1736. DOI: 10.1056/NEJMoa1606910.

64.FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR) | FDA[EB/OL]. (2021-02-04) [2022-03-06]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and.

65.Sandborn WJ, Feagan BG, D'Haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med, 2021, 385(14): 1280-1291. DOI: 10.1056/NEJMoa2033617.

66.Sarangi SC, Pattnaik SS, Sinha S, et al. An update on efficacy and safety comparison of biologics in treatment of  inflammatory bowel disease targeting TNF-alpha, interleukins, leukocyte trafficking,  Janus-kinase, and sphingosine-1-phosphate receptor[J]. Expert Rev Gastroenterol Hepatol, 2022: 1-25. DOI: 10.1080/17474124.2022.2155136.

67.Bots SJ, Parker CE, Brandse JF, et al. Anti-drug antibody formation against biologic agents in inflammatory bowel  disease: a systematic review and meta-analysis[J]. BioDrugs, 2021, 35(6): 715-733. DOI: 10.1007/s40259-021-00507-5.

68.Danese S, Vermeire S, Hellstern P, et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)[J]. Gut, 2019, 68(1): 40-48. DOI: 10.1136/gutjnl-2017-314562.

69.Danese S, Klopocka M, Scherl EJ, et al. Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: a phase 2a single-arm study[J]. Clin Gastroenterol Hepatol, 2021, 19(11): 2324-2332. DOI: 10.1016/j.cgh.2021.06.011.

70.Atreya R, Bloom S, Scaldaferri F, et al. Clinical effects of a topically applied toll-like receptor 9 agonist in active moderate-to-severe ulcerative colitis[J]. J Crohns Colitis, 2016, 10(11): 1294-1302. DOI: 10.1093/ecco-jcc/jjw103.

71.Danese S, Neurath MF, Kopon A, et al. Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized  trial of patients with active ulcerative colitis[J]. Clin Gastroenterol Hepatol, 2020, 18(11): 2526-2534. DOI: 10.1016/j.cgh.2019.12.032.

72.Leber A, Hontecillas R, Zoccoli-Rodriguez V, et al. The safety, tolerability, and pharmacokinetics profile of BT-11, an oral, gut-restricted lanthionine synthetase c-like 2 agonist investigational new drug for inflammatory bowel disease: a randomized, double-blind, placebo-controlled  phase I clinical trial[J]. Inflamm Bowel Dis, 2020, 26(4): 643-652. DOI: 10.1093/ibd/izz094.

73.Li Y, Chen J, Bolinger AA, et al. Target-based small molecule drug discovery towards novel therapeutics for inflammatory bowel diseases[J]. Inflamm Bowel Dis, 2021, 27(Suppl 2): S38-S62. DOI: 10.1093/ibd/izab190.

74.Vermeire S, Hebuterne X, Tilg H, et al. Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: results of phase IIa trial[J]. Gastroenterology, 2021, 160(7): 2595-2598. DOI: 10.1053/j.gastro.2021.02.054.